Amoéba wins SIVAL gold and outlines plans for its biocontrol solution.

Amoéba won the SIVAL Innovation 2026 gold medal for its AXPERA biocontrol solution and, with partner Koppert, said it will market the product as TIAGAN pending marketing authorisations in nine European countries expected in the first half of 2026.

Amoéba presented its biocontrol solution at the SIVAL exhibition in Angers and was awarded the SIVAL Innovation 2026 gold medal. The company and partner Koppert described the product under the AXPERA name, with TIAGAN announced as the commercial brand for viticulture uses. Amoéba says the solution targets fungal diseases such as grapevine downy mildew and aims to reduce reliance on copper. The company is preparing production and supply-chain capacity while awaiting regulatory decisions in Europe. Key facts: - Amoéba received the SIVAL Innovation 2026 gold medal in the 'plant health, soil and growing media' category for its AXPERA solution. - Koppert announced TIAGAN as the commercial brand that will replace AXPERA for viticultural uses and the partners plan a 2026 launch pending approvals. - Marketing authorisations are pending in nine targeted European countries, with decisions expected in the first half of 2026. - The article reports that the active substance received approval in the USA in 2022 and in Europe in 2025, and that product approvals have been granted in the USA and are expected in Europe in the coming months. - Amoéba says it is investing in CDMOs and other production capacity to prepare for a commercial ramp-up and is focusing initial marketing on vineyards and vegetable crops. Summary: The SIVAL award adds industry recognition to Amoéba's development of a biological fungicide and supports its commercial plans with Koppert. The immediate next steps reported are regulatory decisions on marketing authorisations in the targeted European countries in the first half of 2026 and continued preparation for production scale-up.